Greenlight Capital’s Gain Therapeutics GANX Stock Holding History

Greenlight Capital’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.92M	Hold	588,410	–	–	0.09%	33
2023 Q3	$1.93M	Buy	588,410 +41,850	+8%	+$159K	0.11%	30
2023 Q2	$2.45M	Hold	546,560	–	–	0.11%	30
2023 Q1	$2.63M	Hold	546,560	–	–	0.14%	29
2022 Q4	$1.71M	Hold	546,560	–	–	0.12%	31
2022 Q3	$1.78M	Hold	546,560	–	–	0.13%	31
2022 Q2	$1.97M	Hold	546,560	–	–	0.15%	35
2022 Q1	$2.24M	Hold	546,560	–	–	0.14%	39
2021 Q4	$2.97M	Hold	546,560	–	–	0.17%	40
2021 Q3	$4.07M	Hold	546,560	–	–	0.27%	32
2021 Q2	$5.47M	Hold	546,560	–	–	0.34%	34
2021 Q1	$8.15M	Buy	+546,560	New	+$7.17M	0.57%	28

Other funds holding GANX

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Greenlight Capital's GANX Position: Q4 2023 in Review

Greenlight Capital held its Gain Therapeutics (GANX) position steady in Q4 2023 at 588,410 shares worth $1.92M. The position accounts for 0.09% of the portfolio, ranked #33.

Greenlight Capital first reported a position in GANX in Q1 2021 and has held it in 12 quarters since. The position peaked at $8.15M in Q1 2021. 24 funds tracked by Wall St. Rank hold GANX as of Q4 2023.

Greenlight Capital held 588,410 shares of Gain Therapeutics worth $1.92M as of Q4 2023.
Greenlight Capital left its Gain Therapeutics share count unchanged in Q4 2023.
Gain Therapeutics made up 0.09% of Greenlight Capital's portfolio in Q4 2023, its #33 holding.
Greenlight Capital first reported a position in Gain Therapeutics in Q1 2021 and has held it in 12 quarters since.
Greenlight Capital's Gain Therapeutics position peaked at $8.15M in Q1 2021.
24 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2023.

Based on Greenlight Capital's 13F filing for Q4 2023, filed 14 Feb 2024.